体形表型与亚临床动脉粥样硬化的关联
这项横断面研究纳入3909名无心血管病的中年无症状受试者,按BMI和心血管代谢异常将体形分为6种表型,评估其与亚临床动脉粥样硬化的关联。结果显示,在代谢健康者中亚临床动脉粥样硬化患病率随BMI升高而增加(NW 49.6%、OW 58.0%、OB 67.7%),而代谢不健康者差异较小(61.1%、69.7%、70.5%)。调整后,体形表型与亚临床动脉粥样硬化的关联主要由心血管代谢危险因素共存驱动。
要点
- 代谢健康者中亚临床动脉粥样硬化患病率随BMI升高而增加。
- 代谢不健康者中亚临床动脉粥样硬化患病率在各BMI类别间差异较小。
- 体形表型与亚临床动脉粥样硬化的关联主要由心血管代谢危险因素数量驱动。
核心结论
- 亚临床动脉粥样硬化患病率因体形表型而异。
- 体形表型与亚临床动脉粥样硬化的关联主要由心血管代谢危险因素共存驱动。
研究设计与样本
- 横断面研究,纳入3909名无心血管病的中年无症状受试者。
- 根据至少1项心血管代谢异常和BMI定义6种体形表型。
- 亚临床动脉粥样硬化通过二维血管超声和非增强心脏计算机断层扫描评估。
主要发现
- 代谢健康者中亚临床动脉粥样硬化患病率:NW 49.6%、OW 58.0%、OB 67.7%。
- 代谢不健康者中亚临床动脉粥样硬化患病率:NW 61.1%、OW 69.7%、OB 70.5%。
- 与NW相比,OW的调整OR=1.04(95%CI 0.90-1.19),OB的调整OR=1.07(95%CI 0.88-1.30)。
- 与无心血管代谢异常者相比,1、2、3和>3项异常的调整OR分别为1.21(95%CI 1.05-1.40)、1.60(95%CI 1.33-1.93)、1.92(95%CI 1.48-2.50)和2.27(95%CI 1.67-3.09)。
临床怎么用
- 临床评估亚临床动脉粥样硬化风险时,应关注心血管代谢异常的数量而非仅依赖BMI。
- 通过药物和生活方式干预促进体形表型向代谢健康转变,可能有助于降低心血管风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The underlying relationship between body mass index (BMI), cardiometabolic disorders, and subclinical atherosclerosis is poorly understood. OBJECTIVE: To evaluate the association between body size phenotypes and subclinical atherosclerosis. DESIGN: Cross-sectional. SETTING: Cardiovascular disease-free cohort. PARTICIPANTS: Middle-aged asymptomatic subjects (n = 3909). A total of 6 cardiometabolic body size phenotypes were defined based on the presence of at least 1 cardiometabolic abnormality (blood pressure, fasting blood glucose, triglycerides, low high-density lipoprotein cholesterol, homeostasis model assessment-insulin resistance index, high-sensitivity C-reactive protein) and based on BMI: normal-weight (NW; BMI <25), overweight (OW; BMI = 25.0-29.9) or obese (OB; BMI >30.0). MAIN OUTCOME MEASURES: Subclinical atherosclerosis was evaluated by 2D vascular ultrasonography and noncontrast cardiac computed tomography. RESULTS: For metabolically healthy subjects, the presence of subclinical atherosclerosis increased across BMI categories (49.6%, 58.0%, and 67.7% for NW, OW, and OB, respectively), whereas fewer differences were observed for metabolically unhealthy subjects (61.1%, 69.7%, and 70.5%, respectively). When BMI and cardiometabolic abnormalities were assessed separately, the association of body size phenotypes with the extent of subclinical atherosclerosis was mostly driven by the coexistence of cardiometabolic risk factors: adjusted OR = 1.04 (95% confidence interval [CI], 0.90-1.19) for OW and OR = 1.07 (95% CI, 0.88-1.30) for OB in comparison with NW, whereas there was an increasing association between the extent of subclinical atherosclerosis and the number of cardiometabolic abnormalities: adjusted OR = 1.21 (95% CI, 1.05-1.40), 1.60 (95% CI, 1.33-1.93), 1.92 (95% CI, 1.48-2.50), and 2.27 (95% CI, 1.67-3.09) for 1, 2, 3, and >3, respectively, in comparison with noncardiometabolic abnormalities. CONCLUSIONS: The prevalence of subclinical atherosclerosis varies across body size phenotypes. Pharmacologic and lifestyle interventions might modify their cardiovascular risk by facilitating the transition from one phenotype to another.
引用
- Rossello X, Fuster V, Oliva B, et al. Association Between Body Size Phenotypes and Subclinical Atherosclerosis. J Clin Endocrinol Metab. 2020. PMID: 32879953. doi:10.1210/clinem/dgaa620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。